Orlando, FL Clinical Trials Report — July 2026

Orlando participants should act promptly on the 31 recruiting trials expected to close within the next 90 days. These include studies involving advanced solid tumors, breast cancer, prostate cancer, major depressive disorder, hepatic impairment, and other conditions. Seven of the closing studies accept healthy volunteers, while 63 healthy-volunteer trials are recruiting across Orlando overall.

The city currently has 699 recruiting clinical trials across 353 research facilities. July brought 7 new openings, a sharp decline from 21 in June and 16 in May. That slower pace makes the active pipeline, particularly studies with near-term closing dates, more important for people looking for a local opportunity.

Closing-soon studies span cancer, mental health, and other conditions

People who may qualify should contact study teams soon because enrollment can end before a projected closing date if a trial reaches its participant target. The main condition areas among Orlando’s closing trials are:

• Advanced solid tumor (2 trials)
• Breast cancer (2 trials)
• Major depressive disorder (2 trials)
• Prostate cancer (2 trials)
• Hepatic impairment (2 trials)
• Chemotherapy-induced pain and chemotherapy-induced neuropathic pain (1 each)
• Atopic dermatitis, colorectal cancer, and chronic subdural hematoma (1 each)

Seven of these closing-soon studies accept healthy volunteers. Eligibility may still depend on age, medications, laboratory results, medical history, and the time commitment required for visits or procedures. People with cancer, depression, liver-related conditions, or the other listed conditions should review individual eligibility requirements rather than assuming a condition alone is sufficient.

Large Phase 3 studies open in obesity, lung cancer, and ADHD

Five of July’s new trials are drug studies, alongside one device study and one procedure study. Industry sponsors account for 5 new trials, while two are classified as other. Several large Phase 3 studies from major sponsors stand out:

• Amgen is sponsoring NCT07684235, a Phase 3 extension study of maridebart cafraglutide for people with obesity or overweight. The trial plans to enroll 3,200 participants and evaluates long-term efficacy, safety, and tolerability.
• Novo Nordisk is sponsoring NCT07720271, the Phase 3 AMAZE 9 study of once-daily zenagamtide tablets for people with excess body weight. The study expects 950 participants and compares zenagamtide with placebo.
• Bristol-Myers Squibb is sponsoring NCT07680790, a Phase 3 study for previously untreated, locally advanced or metastatic EGFR-mutant non-small cell lung cancer. It compares izalontamab brengitecan combined with osimertinib against osimertinib alone or osimertinib with platinum-based chemotherapy in a planned population of 850 participants.
• Axsome Therapeutics is sponsoring NCT07717879, a Phase 3 study of solriamfetol in children aged 6 to under 12 with ADHD. The planned enrollment is 468 participants.
• Axsome Therapeutics is also sponsoring NCT07717892, a companion Phase 3 study in adolescents aged 12 to under 18 with ADHD, also planning to enroll 468 participants.

The new-trial mix reflects Orlando’s broad research activity. ADHD, obesity, and overweight each appear in 2 new trials. Additional openings involve non-small cell lung cancer, non-resectable pancreatic cancer, pancreatic duct obstruction, acute cholecystitis, pancreatic fluid collections, biliary obstruction, and chronic pancreatitis.

AdventHealth and Orlando Health lead local access

The largest concentration of recruiting studies is at hospital systems and specialty research centers. AdventHealth Orlando leads the local list with 57 trials. Nemours Children’s Hospital and Arnold Palmer Hospital for Children provide especially strong options for pediatric research, while Orlando Health Cancer Institute is a major destination for oncology studies.

• AdventHealth Orlando (57 trials)
• Nemours Children’s Hospital (39 trials)
• Arnold Palmer Hospital for Children (37 trials)
• Orlando Health Cancer Institute (35 trials)
• Orlando Health (32 trials)
• AdventHealth (28 trials)
• Research Site (27 trials)
• University of Central Florida (26 trials)
• Advent Health (17 trials)
• Orlando Clinical Research Center (15 trials)
• Florida Cancer Specialists (12 trials)
• Advent Health Orlando (11 trials)

For families, Nemours Children’s Hospital and Arnold Palmer Hospital for Children are the clearest starting points because two of the new trials include children. Orlando Health Cancer Institute and Florida Cancer Specialists may be particularly relevant for people exploring oncology studies. The University of Central Florida and Orlando Clinical Research Center broaden access to academic and community-based research beyond hospital cancer programs.

Healthy volunteers and eligibility details

None of July’s 7 new trials accepts healthy volunteers, so people without a diagnosed condition may find better opportunities among the 63 healthy-volunteer studies already recruiting in Orlando. New openings include 2 studies that include children and 5 that include older adults. No new trial is limited to females or males.

Orlando Health, Inc. and Axsome Therapeutics each sponsor 2 of the new studies. Amgen, Bristol-Myers Squibb, and Novo Nordisk each sponsor one. These sponsors provide a mix of late-stage drug development and locally delivered research, but participation still depends on the site’s enrollment status and each study’s screening criteria.

Other Florida cities offer additional options

Participants willing to travel can also search nearby Florida research markets. Miami has 15 recruiting trials, followed by Tampa with 13. Coral Gables and Hollywood each have five, as do Fort Myers and Jacksonville. Miami Lakes has four, while Fort Lauderdale has three.

After July’s slowdown, the monthly new-trial trend shows 19 openings in February and March, 12 in April, 16 in May, 21 in June, and seven in July; the dataset lists three for August. Patients and volunteers who find a promising match should verify the site’s current availability and begin prescreening early, as local opportunities may change quickly through the rest of the summer.